Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.

International journal of clinical and experimental pathology - 1 Jan 2013

Zhang Hai-Hong, Zhang Zhi-Yi, Che Chun-Li, Mei Yi-Fang, Shi Yu-Zhi

Abstract excerpt

Gemcitabine is one of the most widely used drugs for the treatment of advanced Non-small cell lung cancer (NSCLC), but modest objective response rate of patients to gemcitabine makes it necessary to identify novel biomarkers for patients who can benefit from gemcitabine-based therapy and to improve the effect of clinical therapy. In this work, 3 NSCLC cell lines displaying different sensitivities to gemcitabine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Drug Screening Assays, Antitumor

Share to Gemcitabine

Share to Gene Regulatory Networks

Share to Inhibitory Concentration 50

Share to Patient Selection

Source

Open in PubMed Open full text

Identifiers

PMID: 24040438
PMCID: PMC3759480

Genes

BCL2
IGF1
NRP2
RAB23
ARHGAP5
CDH2
CXCR3
GNA13
HLF
IGSF3
IKBKB
MAF
SOD3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.PMID 24040438Read ↗

Identification of Biomarker Signatures and Candidate Drugs in Non-Small Cell Lung CancerSemantic proximity Read ↗

Role of the long non-coding RNAs in regulation of Gemcitabine response in tumor cellsSemantic proximity Read ↗

Transcriptome Sequencing Reveals Key Pathways and Genes Associated with Cisplatin Resistance in Lung Adenocarcinoma A549 CellsSemantic proximity Read ↗

Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft ModelsSemantic proximity Read ↗

Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read ↗

Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application.Semantic proximity Read ↗

Pharmacogenomics of Gemcitabine in Non-Small-Cell Lung Cancer and Other Solid TumorsSemantic proximity Read ↗

Screening prognostic markers for non-small cell lung cancer based on data mining and bioinformatics analysisSemantic proximity Read ↗

ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancerSemantic proximity Read ↗

A 14-gene gemcitabine resistance gene signature is significantly associated with the prognosis of pancreatic cancer patientsSemantic proximity Read ↗

Hsa-miR-195-5p Inhibits Autophagy and Gemcitabine Resistance of Lung Adenocarcinoma Cells via E2F7/CEP55Semantic proximity Read ↗

N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by activating the Wnt signaling pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.